- Home
- LPAA vs BMEA Comparison
LPAA vs BMEA Comparison
Compare LPAA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPAA | BMEA |
|---|---|---|
| Founded | 2024 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.3M | 96.9M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LPAA | BMEA |
|---|---|---|
| Price | $10.58 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.71 |
| AVG Volume (30 Days) | 56.0K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.01 | $0.87 |
| 52 Week High | $10.70 | $4.62 |
Technical Indicators
Market Signals| Indicator | LPAA | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 70.32 | 52.63 |
| Support Level | $10.52 | $0.95 |
| Resistance Level | $10.59 | $1.42 |
| Average True Range (ATR) | 0.02 | 0.14 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 100.00 | 64.75 |
Price Performance
Historical ComparisonAbout LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.